← Back to Search

Other

Relacorilant for Cushing Syndrome

Phase 1
Waitlist Available
Research Sponsored by Corcept Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days post final dose
Awards & highlights

Study Summary

This trial is looking at how a drug called relacorilant affects the levels of another drug, dabigatran etexilate, in the body.

Eligible Conditions
  • Cushing Syndrome
  • Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 days post final dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 days post final dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area Under the Curve from Time 0 Extrapolated to Infinity (AUC 0-inf) of Dabigatran When Administered With and Without Relacorilant
Area Under the Curve from Time 0 to the Time of Last Measurable Concentration (AUC0-last) of Dabigatran When Administered With and Without Relacorilant
Maximum Observed Plasma Concentration (Cmax) of Dabigatran When Administered With and Without Relacorilant
Secondary outcome measures
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of Participants with Clinically Significant Abnormalities in Blood Pressure and Heart Rate
Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECG) Measurements
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dabigatran Etexilate (NIMP) and Relacorilant (IMP)Experimental Treatment2 Interventions
Following an overnight fast, participants will receive 75 mg dabigatran etexilate on Day 1, 400 mg dose of relacorilant QD on Days 3 to 13, and 75 mg dabigatran etexilate on Day 12. On Day 12, dabigatran etexilate will be dosed at approximately the same time as the relacorilant dose.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Relacorilant
Not yet FDA approved
Dabigatran
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Corcept TherapeuticsLead Sponsor
68 Previous Clinical Trials
6,350 Total Patients Enrolled
12 Trials studying Cushing Syndrome
1,530 Patients Enrolled for Cushing Syndrome
Joseph Custodio, PhDStudy DirectorCorcept Therapeutics
4 Previous Clinical Trials
150 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
2022. "Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05347979.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top